Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Current Assets (2021 - 2026)

Centessa Pharmaceuticals has reported Current Assets over the past 5 years, most recently at $367.9 million for Q4 2025.

  • Quarterly Current Assets fell 31.42% to $367.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $367.9 million through Dec 2025, down 31.42% year-over-year, with the annual reading at $367.9 million for FY2025, 31.42% down from the prior year.
  • Current Assets was $367.9 million for Q4 2025 at Centessa Pharmaceuticals, up from $307.7 million in the prior quarter.
  • Over five years, Current Assets peaked at $628.8 million in Q4 2021 and troughed at $284.5 million in Q1 2024.
  • The 5-year median for Current Assets is $367.9 million (2025), against an average of $417.3 million.
  • Year-over-year, Current Assets soared 70.96% in 2024 and then plummeted 45.87% in 2025.
  • A 5-year view of Current Assets shows it stood at $628.8 million in 2021, then plummeted by 30.38% to $437.7 million in 2022, then fell by 28.02% to $315.1 million in 2023, then surged by 70.24% to $536.4 million in 2024, then plummeted by 31.42% to $367.9 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Current Assets are $367.9 million (Q4 2025), $307.7 million (Q3 2025), and $300.4 million (Q2 2025).